PDX models of human lung squamous cell carcinoma: Consideration of factors in preclinical and co-clinical applications
- 주제(키워드) Engraftment , Lung squamous cell carcinoma , Patient-derived xenograft , Preclinical model , Xenograft-associated lymphoproliferative disease
- 등재 SCIE, SCOPUS
- OA유형 gold, Green Published
- 발행기관 BioMed Central
- 발행년도 2020
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000172280
- 본문언어 영어
- Published As https://dx.doi.org/10.1186/s12967-020-02473-y
- PubMed https://pubmed.ncbi.nlm.nih.gov/32762722
- 저작권 이화여자대학교 논문은 저작권에 의해 보호받습니다.
초록/요약
Background: Treatment of human lung squamous cell carcinoma (LUSC) using current targeted therapies is limited because of their diverse somatic mutations without any specific dominant driver mutations. These mutational diversities preventing the use of common targeted therapies or the combination of available therapeutic modalities would require a preclinical animal model of this tumor to acquire improved clinical responses. Patient-derived xenograft (PDX) models have been recognized as a potentially useful preclinical model for personalized precision medicine. However, whether the use of LUSC PDX models would be appropriate enough for clinical application is still controversial. Methods: In the process of developing PDX models from Korean patients with LUSC, the authors investigated the factors influencing the successful initial engraftment of tumors in NOD scid gamma mice and the retainability of the pathological and genomic characteristics of the parental patient tumors in PDX tumors. Conclusions: The authors have developed 62 LUSC PDX models that retained the pathological and genomic features of parental patient tumors, which could be used in preclinical and co-clinical studies. Trial registration Tumor samples were obtained from 139 patients with LUSC between November 2014 and January 2019. All the patients provided signed informed consents. This study was approved by the institutional review board (IRB) of Samsung Medical Center (2018-03-110) © 2020 The Author(s).
more